We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A Landscape Assessment of Newborn Screening in Europe
Industry Insight

A Landscape Assessment of Newborn Screening in Europe

A Landscape Assessment of Newborn Screening in Europe
Industry Insight

A Landscape Assessment of Newborn Screening in Europe


Want a FREE PDF version of This Industry Insight?

Complete the form below and we will email you a PDF version of "A Landscape Assessment of Newborn Screening in Europe"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Newborn screening (NBS), or the process of identifying members of a population who may have, or may be at risk of developing, a specific disease or condition, has become an integral part of many public health programs in recent years.1 NBS programs have helped minimize patient suffering, which often results from extended diagnostic pathways, and have also played a role in diminishing the longer-term disease burden on healthcare systems by offering the prospect of early diagnosis and treatment. The benefits of NBS are well established but there are disparities across Europe in the number of diseases included in the panel of tests conducted on newborns – ranging from more than 25 diseases in some countries to as few as 2 in others. As the treatment landscape for rare diseases and gene therapies evolves and more therapies become available, the role of NBS as a critical driver of value and efficiency for European healthcare systems is poised to increase.


To better understand the differences in the composition and functioning of NBS programs across Europe, our team at CRA conducted a comparative analysis of specific policies governing periodic updates to NBS panels and explored the role of stakeholders involved in this process in 30 European countries. Our findings showed the need for policy changes to make NBS programs more patient focused and better fit for purpose and the role that decision making stakeholders should play in optimizing the positive impact of NBS programs on patients and healthcare systems in the future.


Current European NBS landscape


Based on our analysis, there are significant disparities between European countries in the number and types of diseases that are included in national NBS programs. Some countries such as Italy, Portugal and Austria screen for more than 25 diseases as part of their national panel,* with Italy leading the way by screening for more than 45 diseases. In contrast, many countries screen for significantly fewer diseases, with the UK and France both testing for less than 10 diseases in their national panels, while Romania and Cyprus are only testing for 2.


There are also disparities in the frequency that each disease is included across NBS programs, with phenylketonuria (PKU) and congenital hypothyroidism (CHT) universally screened for across all 30 countries in-scope. These diseases have a relatively high incidence compared to other screened diseases (both have incidences of greater than 1 in 10,000 whereas other diseases included in programs can have incidence rates as low as 1 in 250,000).2 However, there are other diseases that have similarly high incidence rates, such as spinal muscular atrophy (SMA) and sickle cell disease (SCD), that are nationally screened for in less than 30% of European countries.


Comparisons of the key characteristics of NBS programs across countries also provide some insights into differences in access to NBS, including factors such as:


Program governance – Some NBS programs are run by national governing bodies, whereas others are run at the regional level, creating disparities within even a single country. For example, in Spain, some autonomous regions such as Catalonia test for more than 20 different diseases, whereas the national program tests for less than 10 diseases. 


Review process – There are notable differences in the evaluation criteria and process by which countries update their NBS programs, with some, such as the UK, conducting reviews annually and others, such as Germany, on an ad hoc basis.


Time to implementation – There are significant disparities in the time it takes to implement changes to NBS programs including approval of inclusion of new diseases across countries. Some countries (e.g., Denmark, Belgium, UK) take less than one year and others (e.g., Greece, Romania, Portugal) take three or more years to put decisions into effect.

 


Figure 1: Mapping of disease inclusion in NBS panels across 30 European countries

Source: CRA analysis. Click on image to enlarge. 


Key barriers to panel expansion and implementation


Many countries have set goals to improve NBS, with government objectives typically published in rare disease plans or national policies. National policies often act as a driver to include more diseases in NBS panels in some countries while in others policymakers have indicated their intent for program and national policy improvements, but still there have been limited or no national panel expansions. Government mandates to improve NBS programs are important, but there are other key factors that often drive NBS panel expansion:


1.    Factors affecting proposals for disease inclusion in NBS panels

The involvement of relevant decision-making stakeholders (e.g., HTA bodies or screening committees) in proposals for disease inclusion in NBS panels. Factors that impact this include: the involvement of non-decision-making stakeholders (e.g., patient advocacy groups) in increasing awareness and knowledge of a disease; the transparency, consistency and ease of proposal submission processes; and relevant resources and funding to support consideration of screening for additional diseases.


2.    Factors affecting review and approval

The review and approval of additions or withdrawals of diseases from NBS panels. This involves ensuring that the evaluation criteria for inclusion or exclusion are appropriate, clear and transparent, that timelines for review are carried out efficiently, and that external stakeholders are involved in evaluation processes so that they can provide specialist expertise or important patient perspectives.


3.    Factors affecting implementation

The implementation process and the adherence to any timelines will depend on several factors including having the required infrastructure, procurement policies, funding and clinical expertise to carry out testing. Political willingness to support implementation timelines is also critical, as highlighted by policy in the UK, which mandates implementation in England and Wales within one year of approval.

 

Table 1: Barriers and best practices to improving NBS


Policy recommendations


Based on the identification of barriers and best practices, we have developed a set of recommendations for policymakers and other key stakeholders with influence on the NBS policy environment to implement to address any challenges and support future NBS panel expansion:


1.    Factors affecting proposals for disease inclusion

  • NBS decision-making bodies should ensure regular consideration of proposed additional tests, as seen in countries such as the UK and Norway.
  • Periodic review processes should be implemented for diseases already included in NBS programs to mitigate declines in the risk-benefit profile and highlight whether a disease should no longer be included in an NBS panel.
  • Engagement of key stakeholders such as patient advocacy groups and clinicians who can drive political support for the establishment of national screening committees and encourage NBS expansion.
  • Payers should ensure sufficient funding is in place for program expansion, within scope.
  • International collaboration among healthcare decision-makers is needed to support broader considerations of evidence-based expansion proposals by aligning on consistent criteria for including new diseases in NBS programs.

 

2.    Factors affecting review and approval

  • Decision-making bodies should be transparent in stating their processes, evaluation criteria and evidence requirements to facilitate the submission of proposals for panel expansion.
  • NBS decision-making bodies across (and within) countries should ensure their criteria are aligned to promote efficient evaluation processes.
  • Authorities should consult patient and clinician representatives at each stage of the expansion process to evaluate the inclusion of additional diseases in the screening panel.
  • Authorities should commit to explaining how stakeholder opinions are evaluated and considered in decision-making processes to increase transparency.
  • Assessments should consider the availability and clinical benefit of relevant treatments when determining the potential value of a screening test for a specific disease. 

 

3.    Factors affecting implementation

  • Countries should conduct mapping exercises of current laboratory locations and capabilities to ensure that future updates to NBS programs are implemented in a timely manner.
  • Timely implementation of NBS needs to be incentivized through policy directives.

 

While there have been developments in NBS programs across Europe in recent years, the increasing availability of genetic testing and advanced screening techniques, coupled with new highly effective treatments, should prompt countries to expand their programs further. More efficient and accelerated processes for NBS panel expansion will help align the advancement of these programs with the speed of medical innovation, maximizing the benefit delivered to patients and healthcare systems.

 

The views expressed herein are the authors’ and not those of Charles River Associates (CRA) or any of the organizations with which the authors are affiliated.


Tim Wilsdon is a vice president, Rowan Saada is an associate and Milan Ferguson is an associate in the Life Sciences Practice at Charles River Associates (CRA).


* Within the context of NBS, “panel” is a term used to describe the selection of diseases/disorders that are currently tested for as part of a NBS program.


References

1. Kelly N, Makarem DC, Wasserstein MP. Screening of newborns for disorders with high benefit-risk ratios should be mandatory. J Law Med Ethics. 2016;44(2): 231-240. doi: 10.1177/1073110516654133.

2. Prevalence and incidence of rare diseases: Bibliographic data. Orphanet Report Series. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Published January 2021. Accessed November 3, 2021.

  

Abbreviations


2M3HBA = 2-Methyl 3-hydroxy butyric aciduria 

2MBG = 2-Methyl butyryl-CoA dehydrogenase deficiency 

3MCC = Deficit of 3-methylcrotonyl-CoA carboxylase deficiency 

3MGCA = 3-methyl glutaconic acids 

ALD = Adrenoleukodystrophy 

ARG = Arginase deficiency 

ASA = Argininosuccinic aciduria 

A-T = Alpha Thalassemia 

BIOPT (BS) = Biopterin cofactor biosynthesis deficiency 

BIOPT (REG) = Biopterin cofactor regeneration deficiency 

BKT = Deficit of Beta-ketothiolase 

B-T = Beta thalassemia 

BTD = Defect of biotinidase

CACT = Carnitine / acyl-carnitine translocase deficiency 

CAH = Congenital Adrenal Hyperplasia 

Cbl A = Methylmalonic acidemia (CblA) 

Cbl B = Methylmalonic acidemia (CblB) 

Cbl C = Methylmalonic Acidemia with Homocystinuria (CblC) 

Cbl D = Methylmalonic Acidemia with Homocystinuria (CblD) 

CF = Cystic Fibrosis 

CHT = Congenital Hypothyroidism   

CIT = Citrullinemia type I 

CIT II = Citrullinemia type II (Citrine deficiency) 

CPT I = Carnitine palmitoyl-transferase (L) deficiency 

CPT II = Carnitine palmitoyl-transferase II deficiency 

CUD = Lack of carnitine transport 

EXP = Short-chain acyl CoA dehydrogenase deficiency   

FABRY = Fabry Disease 

G6PD = Glucose-6-phosphate dehydrogenase 

GA I = Glutaric acidemia type I 

GA2 = Glutaric acidemia type II 

GAL = Galactosemia 

GALK = Galactokinase deficiency 

GBA = Gaucher disease

GNMT = Glycine N-methyltransferase deficiency 

HCU = Homocystinuria (CBS deficiency) 

HMG = 3-Hydroxy 3-methyl glutaric aciduria 

H-PHE = Benign hyperphenylalaninemia 

IBG = Isobutyrril-CoA dehydrogenase deficiency

IVA = Isovaleric acidemia 

LCHAD = Long-chain hydroxyacyl CoA dehydrogenase deficiency 

M / SCHAD = Short / medium chain 3-OH acyl-CoA dehydrogenase deficiency 

MADD = Multiplex acyl-CoA dehydrogenase deficiency   

MAL = Malonic aciduria 

MAT = Methionine adenosyltransferase deficiency 

MCAD = Medium-chain acyl CoA dehydrogenase deficiency 

MCD = Multiple carboxylase deficiency 

MLD = Metachromatic leukodystrophy

MMA = Vitamin B12 deficiency 

MPS I = Type I mucopolysaccharidosis 

MSUD = Maple syrup urine disease 

MTHFR = Homocystinuria due to MTHFR deficiency 

MUT = Methylmalonic acidemia (Mut) 

ORN = Osteoradionecrosis

OTC = Ornithine transcarbamylase deficiency 

PA = Propionic Acidemia

PKU = Phenylketonuria 

POMPE = Pompe Disease 

SAHH = Deficit of S-adenosylhomocysteine hydrolase 

SCD = Sickle cell disease 

SCID = Severe combined immunodeficiency   

SMA = Spinal Muscular Atrophy 

TFP = Deficit of the trifunctional protein 

TYR I = Type I tyrosinemia 

TYR II = Tyrosinemia type II 

TYR III = Tyrosinemia type III

VLCAD = Very long chain acyl CoA dehydrogenase deficiency


Advertisement